7月11日周五，Kalvista Pharmaceuticals Inc（股票代码：KALV）股价在盘中大跌5.53%，引起市场关注。这一显著跌幅与公司最新发布的2025财年财报密切相关。
根据Kalvista Pharmaceuticals公布的财报，公司2025财年净亏损达1.83亿美元，同比扩大44.09%。更值得注意的是，公司报告期内营业收入为0美元，每股基本亏损3.69美元。这些数据显示公司面临严峻的财务挑战，可能是导致投资者信心下降的主要原因。
从资产负债状况来看，Kalvista Pharmaceuticals的财务状况同样不容乐观。公司总负债为1.55亿美元，资产负债比高达1.62，而流动比率仅为0.06，表明公司面临较大的财务压力和流动性风险。尽管如此，分析机构对公司前景仍保持谨慎乐观，9家机构给出的平均目标价为30.89美元，最高目标价达40美元。作为一家专注于开发小分子蛋白酶抑制剂的制药公司，Kalvista Pharmaceuticals的未来发展仍值得市场持续关注。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.